Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies
Presentation Monday, June 4, 2018, at ASCO. RGX-104 is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene. To read the abstract, please click here.
Rgenix Announces Publication In Cell Demonstrating Activation of LXR/ApoE with RGX-104 Enhances Antitumor Immunity
LXR/ApoE Pathway Identified as Key Regulator of Innate Immune Suppression in Cancer FOR IMMEDIATE RELEASE New York, NY – January 11, 2018– Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today the publication of clinical
Preliminary Phase 1a/b data demonstrate RGX-104 modulates the innate immune system to stimulate T cell activation in a diverse group of heavily pre-treated patients with refractory solid cancers. Phase 1 dose escalation continues, and future plans include initiation of an expansion
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic
Rgenix Announces Treatment of First Patient in Phase 1 Trial of RGX-104, its Lead Immuno-Oncology Therapeutic First-in-Class Cancer Therapeutic Targets the Liver X Receptor (LXR)-ApoE Pathway Identified Using Rgenix’s Discovery Platform NEW YORK CITY, N.Y., January 6, 2017 – Rgenix, Inc.,